The phase III trial, named SHEPHERD, together with the already enrolling pivotal efficacy trial called TRIUMPH, comprise the phase III paroxysmal nocturnal hemoglobinuria (PNH) program which was agreed
Under the multi-year research collaboration, ComGenex will apply its proprietary Matrix technology, using in silico tools to expedite the design of targeted compound libraries. In addition, ComGenex will
The general meeting of shareholders of Aventis Pasteur, held in December 2004, voted the change in name from Aventis Pasteur to Sanofi Pasteur. The Aventis Pasteur MSD joint
The vascular endothelial growth factor (VEGF) Trap is a member of Regeneron’s proprietary family of “Trap” product candidates. Regeneron has developed patented methods of designing potential therapeutic molecules,
Recently, a team of researchers in the UK set out to test the effectiveness of anti-TNF-alpha therapy on a small sample of patients with very early, poor-prognosis, previously
Aptamera’s principal asset is AGRO100, a novel aptamer drug that has shown promising anticancer effects and a marked lack of side effects in a phase I trial of
There is no change in the US arrangement under which GSK and Bayer (through its distributor Schering-Plough) now co-promote Levitra (vardenafil HCl). Similarly, there will be no change
Clinical trials have demonstrated that adult growth hormone deficiency (AGHD) can be effectively treated with Saizen (somatropin, rDNA origin, for injection). With the US approval, the treatment is
Abraxane is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should
Bonefos (clodronate) is an oral non-amino bisphosphonate intended to reduce the occurrence of bone metastases in the post-surgical (adjuvant) treatment of breast cancer patients. Berlex, Schering’s US affiliate,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.